Daily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial

Most people infected with HIV-1 are dually infected with herpes simplex virus type 2. Daily suppression of this herpes virus reduces plasma HIV-1 concentrations, but whether it delays HIV-1 disease progression is unknown. We investigated the effect of aciclovir on HIV-1 progression. In a trial with...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) Vol. 375; no. 9717; pp. 824 - 833
Main Authors: Lingappa, Jairam R, Baeten, Jared M, Wald, Anna, Hughes, James P, Thomas, Katherine K, Mujugira, Andrew, Mugo, Nelly, Bukusi, Elizabeth A, Cohen, Craig R, Katabira, Elly, Ronald, Allan, Kiarie, James, Farquhar, Carey, Stewart, Grace John, Makhema, Joseph, Essex, Myron, Were, Edwin, Fife, Kenneth H, de Bruyn, Guy, Gray, Glenda E, McIntyre, James A, Manongi, Rachel, Kapiga, Saidi, Coetzee, David, Allen, Susan, Inambao, Mubiana, Kayitenkore, Kayitesi, Karita, Etienne, Kanweka, William, Delany, Sinead, Rees, Helen, Vwalika, Bellington, Magaret, Amalia S, Wang, Richard S, Kidoguchi, Lara, Barnes, Linda, Ridzon, Renee, Corey, Lawrence, Celum, Connie
Format: Journal Article
Language:English
Published: Kidlington Elsevier Ltd 06.03.2010
Elsevier
Elsevier Limited
Subjects:
ISSN:0140-6736, 1474-547X
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first